drugset / Trial / NCT04457258

68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma

NCT04457258 ↗

NaSingle-groupOpen-labelDiagnostic

Summary

This early phase I trial studies an imaging technique called 68Ga-FAPi-46 PET/CT to determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues in patients with sarcoma. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 68Ga-FAPi. Because some cancers take up 68Ga-FAPi it can be seen with PET. CT utilizes x-rays that traverse body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient's body.

Timeline

Start
2020-09-08
Primary completion
2026-12-02
Completion
2027-12-02

Drugs

EvaluationDrugModalityDoseRoute
Subject FAPI-46 GA-68 Diagnostic / imaging agent — Intravenous

Indications